Reforestation of Cunninghamia lanceolata changes the relative abundances of important prokaryotic families in soil.

Over the past decades, many forests have been converted to monoculture plantations, which might affect the soil microbial communities that are responsible for governing the soil biogeochemical processes. Understanding how reforestation efforts alter soil prokaryotic microbial communities will therefore inform forest management. In this study, the prokaryotic communities were comparatively investigated in a secondary Chinese fir forest (original) and a reforested Chinese fir plantation (reforested from a secondary Chinese fir forest) in Southern China. The results showed that reforestation changed the structure of the prokaryotic community: the relative abundances of important prokaryotic families in soil. This might be caused by the altered soil pH and organic matter content after reforestation. Soil profile layer depth was an important factor as the upper layers had a higher diversity of prokaryotes than the lower ones (p < 0.05). The composition of the prokaryotic community presented a seasonality characteristic. In addition, the results showed that the dominant phylum was Acidobacteria (58.86%) with Koribacteraceae (15.38%) as the dominant family in the secondary Chinese fir forest and the reforested plantation. Furthermore, soil organic matter, total N, hydrolyzable N, and NH4+-N were positively correlated with prokaryotic diversity (p < 0.05). Also, organic matter and NO3--N were positively correlated to prokaryotic abundance (p < 0.05). This study demonstrated that re-forest transformation altered soil properties, which lead to the changes in microbial composition. The changes in microbial community might in turn influence biogeochemical processes and the environmental variables. The study could contribute to forest management and policy-making.

Synthesis, biological evaluation and molecular docking study of N-(2-methoxyphenyl)-6-((4-nitrophenyl)sulfonyl)benzamide derivatives as potent HIV-1 Vif antagonists.

Viral infectivity factor (Vif) is protective against APOBEC3G (A3G)-mediated viral cDNA hypermutations, and development of molecules that inhibit Vif mediated A3G degradation is a novel strategy for blocking HIV-1 replication. Through optimizations of the central ring of N-(2-methoxyphenyl)-2-((4-nitrophenyl)thio)benzamide (RN-18), we found a potent compound 12c with EC50 value of 1.54 µM, enhancing the antiviral activity more than 150-fold compared with RN-18 in nonpermissive H9 cells. 12c protected A3G from degradation by inhibiting Vif function. Besides, 12c suppressed different HIV-1 clinical strains (HIV-1KM018, HIV-1TC-1 and HIV-1WAN) and drug-resistant strains (NRTI, NNRTI, PI, and FI) with relatively high activities. Amidation of 12c with glycine gave a prodrug 13a, improving the water solubility about 2600-fold compared with 12c. Moreover, 13a inhibited the virus replication efficiently with an EC50 value of 0.228 µM. These results suggested that the prodrug 13a is a promising candidate agent for the treatment of AIDS.

[The effect of oral alpha-lipoic acid in overweight/obese individuals on brachial-ankle pulse wave velocity and supine blood pressure: a randomized, crossover, double-blind, placebo-controlled trial].

OBJECTIVE: To investigate the effect of oral alpha-lipoic acid (ALA) supplement on brachial-ankle pulse wave velocity (baPWV), supine systolic blood pressure (SBP) and diastolic blood pressure (DBP) in overweight/obese individuals. An 8-week double-blind, randomized, placebo-controlled and cross-over trial with a 4-week washout between cross-over periods. METHODS: Sixty-three males and 40 females aged 22 - 57 years old who met the inclusion criteria as (1) Han ethnicity; (2) 20 - 60 years old; (3) BMI ≥ 25 kg/m(2) and having at least one of the following risk factors: borderline hypertension (130 mm Hg ≤ SBP < 140 mm Hg and/or 85 mm Hg ≤ supine DBP< 90 mm Hg), dyslipidemia (fasting total cholesterol ≥ 5.2 mmol/L or HDL-C < 1.04 mmol/L), or impaired fasting glucose (6.1 mmol/L ≤ fasting glucose < 7.0 mmol/L); (4) Not on any antioxidant vitamin supplement. They were randomly assigned to Group 1 or Group 2 in a 1:1 ratio balanced for gender. Group 1 received 8 weeks ALA (1200 mg/day) followed by 4-week washout period and followed by another 8 weeks placebo; while Group 2 received 8 weeks placebo (1200 mg/day) followed by 4-week washout period, and followed by ALA treatment for 8 weeks. BaPWV and supine blood pressure were measured at the beginning of 1(st) phase and 2(nd) phase and at the endpoint of the whole trial. Mixed effect linear regression model was performed to compare the change of baPWV and supine blood pressure between ALA group and placebo group. RESULTS: BaPWV decreased -33.03 cm/s ± 130.70 cm/s for ALA group and increased 5.66 cm/s ± 139.89 cm/s for placebo group, supine systolic blood pressure decreased -4.09 mm Hg ± 9.18 mm Hg for ALA group and -2.32 mm Hg ± 8.16 mm Hg for placebo group. Supine diastolic blood pressure decreased -1.29 mm Hg ± 6.55 mm Hg for ALA group and -0.48 mm Hg ± 6.63 mm Hg for placebo group. These three mix-effect models did not show significant effect of ALA treatment after adjustment on baseline values, sex, age, treatment sequence or period. CONCLUSION: The current trial did not provide evidence that oral intake of ALA for 8 weeks had significant effects on lowering baPWV, supine systolic blood pressure or supine diastolic blood pressure.